Head & Neck Cancer

Escitalopram for Head and Neck Cancer Patients Cut Depression in Half

Prophylactic use of the SSRI escitalopram decreased the occurrence of depression in patients with head and neck cancers by 50% and resulted in significantly improved quality of life for 3 months after drug cessation, according to the results of the PROTECT trial.

Head & Neck Cancer

Researchers have developed a preliminary test using blood and saliva samples to detect disease recurrence in patients with HPV-related head and neck cancer.

A 74-year-old man presented with a 2.5-cm ulcerated mass occupying the middle third of his left outer ear, approximating the helical rim.

A phase II study demonstrated that cetuximab plus docetaxel-based chemoradiotherapy postoperatively in patients with high-risk squamous cell carcinoma of the head and neck led to improved disease-free and overall survival.

High-risk HPVs may be present more frequently than previously estimated in a variety of head and neck cancers, supporting the use of a combination of methods to detect high-risk strains.

A small retrospective study has identified several biomarkers that were significantly altered in patients with head and neck squamous cell carcinoma. If further validated, these serum biomarkers could facilitate early diagnosis.

Researchers have identified several risk factors that may help predict which patients with oropharyngeal cancer may require a percutaneous endoscopic gastrostomy tube during chemoradiotherapy, according to a newly published review.

Black race did not adversely affect outcomes after receiving radiotherapy for head and neck squamous cell carcinoma compared with white race, according to the results of a study in which black patients made up the majority of enrolled participants.


Subscribe to Head & Neck Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.